                         SEQUENCE LISTING

<110>  Deutsches Krebsforschungszentrum & Galapagos N. V.
 
<120>  Rspondin-3 Inhibition in Bone Disorders

<130>  44793P US

<160>  2     

<170>  PatentIn version 3.3

<210>  1
<211>  2165
<212>  DNA
<213>  Homo sapiens


<220>
<221>  gene
<222>  (1)..(2165)
<223>  human Rspondin-3

<400>  1
gcggccgccc cggcggctcc tggaaccccg gttcgcggcg atgccagcca ccccagcgaa     60

gccgccgcag ttcagtgctt ggataatttg aaagtacaat agttggtttc cctgtccacc    120

cgccccactt cgcttgccat cacagcacgc ctatcggatg tgagaggaga agtcccgctg    180

ctcgggcact gtctatatac gcctaacacc tacatatatt ttaaaaacat taaatataat    240

taacaatcaa aagaaagagg agaaaggaag ggaagcatta ctgggttact atgcacttgc    300

gactgatttc ttggcttttt atcattttga actttatgga atacatcggc agccaaaacg    360

cctcccgggg aaggcgccag cgaagaatgc atcctaacgt tagtcaaggc tgccaaggag    420

gctgtgcaac atgctcagat tacaatggat gtttgtcatg taagcccaga ctattttttg    480

ctctggaaag aattggcatg aagcagattg gagtatgtct ctcttcatgt ccaagtggat    540

attatggaac tcgatatcca gatataaata agtgtacaaa atgcaaagct gactgtgata    600

cctgtttcaa caaaaatttc tgcacaaaat gtaaaagtgg attttactta caccttggaa    660

agtgccttga caattgccca gaagggttgg aagccaacaa ccatactatg gagtgtgtca    720

gtattgtgca ctgtgaggtc agtgaatgga atccttggag tccatgcacg aagaagggaa    780

aaacatgtgg cttcaaaaga gggactgaaa cacgggtccg agaaataata cagcatcctt    840

cagcaaaggg taacctgtgt cccccaacaa atgagacaag aaagtgtaca gtgcaaagga    900

agaagtgtca gaagggagaa cgaggaaaaa aaggaaggga gaggaaaaga aaaaaaccta    960

ataaaggaga aagtaaagaa gcaatacctg acagcaaaag tctggaatcc agcaaagaaa   1020

tcccagagca acgagaaaac aaacagcagc agaagaagcg aaaagtccaa gataaacaga   1080

aatcggtatc agtcagcact gtacactaga gggttccatg agattattgt agactcatga   1140

tgctgctatc tcaaccagat gcccaggaca ggtgctctag ccattaggac cacaaatgga   1200

catgtcagtt attgctctgt ctaaacaaca ttcccagtag ttgctatatt cttcatacaa   1260

gcatagttaa caacaaagag ccaaaagatc aaagaaggga tactttcaga tggttgtctt   1320

gtgtgcttct ctgcattttt aaaagacaag acattcttgt acatattatc aataggctat   1380

aagatgtaac aacgaaatga tgacatctgg agaagaaaca tcttttcctt ataaaaatgt   1440

gttttcaagc tgttgtttta agaagcaaaa gatagttctg caaattcaaa gatacagtat   1500

cccttcaaaa caaataggag ttcagggaag agaaacatcc ttcaaaggac agtgttgttt   1560

tgaccgggag atctagagag tgctcagaat tagggcctgg catttggaat cacaggattt   1620

atcatcacag aaacaactgt tttaagatta gttccatcac tctcatcctg tatttttata   1680

agaaacacaa gagtgcatac cagaattgaa tataccatat gggattggag aaagacaaat   1740

gtggaagaaa tcatagagct ggagactact tttgtgcttt acaaaactgt gaaggattgt   1800

ggtcacctgg aacaggtctc caatctatgt tagcactatg tggctcagcc tctgttaccc   1860

cttggattat atatcaacct gtaaacatgt gcctgtaact tacttccaaa aacaaaatca   1920

tacttattag aagaaaattc tgattttata gaaaaaaaat agagcaagga gaatataaca   1980

tgtttgcaaa gtcatgtgtt ttctttctca atgagggaaa aacaatttta ttacctgctt   2040

aatggtccac ctggaactaa aagggatact attttctaac aaggtatatc tagtagggga   2100

gaaagccacc acaataaata tatttgttaa tagtttttca aaaaaaaaaa aaaaaaaaaa   2160

aaaaa                                                               2165


<210>  2
<211>  272
<212>  PRT
<213>  Homo sapiens


<220>
<221>  PEPTIDE
<222>  (1)..(272)
<223>  human Rspondin-3

<400>  2

Met His Leu Arg Leu Ile Ser Trp Leu Phe Ile Ile Leu Asn Phe Met 
1               5                   10                  15      


Glu Tyr Ile Gly Ser Gln Asn Ala Ser Arg Gly Arg Arg Gln Arg Arg 
            20                  25                  30          


Met His Pro Asn Val Ser Gln Gly Cys Gln Gly Gly Cys Ala Thr Cys 
        35                  40                  45              


Ser Asp Tyr Asn Gly Cys Leu Ser Cys Lys Pro Arg Leu Phe Phe Ala 
    50                  55                  60                  


Leu Glu Arg Ile Gly Met Lys Gln Ile Gly Val Cys Leu Ser Ser Cys 
65                  70                  75                  80  


Pro Ser Gly Tyr Tyr Gly Thr Arg Tyr Pro Asp Ile Asn Lys Cys Thr 
                85                  90                  95      


Lys Cys Lys Ala Asp Cys Asp Thr Cys Phe Asn Lys Asn Phe Cys Thr 
            100                 105                 110         


Lys Cys Lys Ser Gly Phe Tyr Leu His Leu Gly Lys Cys Leu Asp Asn 
        115                 120                 125             


Cys Pro Glu Gly Leu Glu Ala Asn Asn His Thr Met Glu Cys Val Ser 
    130                 135                 140                 


Ile Val His Cys Glu Val Ser Glu Trp Asn Pro Trp Ser Pro Cys Thr 
145                 150                 155                 160 


Lys Lys Gly Lys Thr Cys Gly Phe Lys Arg Gly Thr Glu Thr Arg Val 
                165                 170                 175     


Arg Glu Ile Ile Gln His Pro Ser Ala Lys Gly Asn Leu Cys Pro Pro 
            180                 185                 190         


Thr Asn Glu Thr Arg Lys Cys Thr Val Gln Arg Lys Lys Cys Gln Lys 
        195                 200                 205             


Gly Glu Arg Gly Lys Lys Gly Arg Glu Arg Lys Arg Lys Lys Pro Asn 
    210                 215                 220                 


Lys Gly Glu Ser Lys Glu Ala Ile Pro Asp Ser Lys Ser Leu Glu Ser 
225                 230                 235                 240 


Ser Lys Glu Ile Pro Glu Gln Arg Glu Asn Lys Gln Gln Gln Lys Lys 
                245                 250                 255     


Arg Lys Val Gln Asp Lys Gln Lys Ser Val Ser Val Ser Thr Val His 
            260                 265                 270         


